Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

NCT04830124 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

173

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to business and strategic decision.

Conditions

Cutaneous Melanoma
Mucosal Melanoma

Interventions

DRUG: Nemvaleukin Alfa Subcutaneous
DRUG: Nemvaleukin Alfa Intravenous
DRUG: Nemvaleukin Alfa Intravenous Less Frequent Dosing
DRUG: Pembrolizumab

Sponsor

Mural Oncology, Inc